NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Files Annamycin IND with FDA for Acute Myeloid Leukemia
Shares of Moleculin Biotech (NASDAQ: MBRX) are trading 7% higher this morning following the company’s news that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to study Annamycin in the treatment of relapsed or refractory acute myeloid leukemia (AML). The company expects the FDA will allow the IND to go into effect, which normally occurs within 30 days and would permit Moleculin to begin additional clinical trials of Annamycin. If the IND goes into effect as the company anticipates, it intends to begin clinical trials in the fourth quarter of 2017. "Now that we…







